Evidence map›Paper›PMID 34563512›Full record

ArticleThe American journal of pathology2021

Selective and Marked Blockade of Endothelial Sprouting Behavior Using Paclitaxel and Related Pharmacologic Agents.

Prisca K Lin, Jocelynda Salvador, Jun Xie, Kalia N Aguera, Gretchen M Koller, Scott S Kemp, Courtney T Griffin, George E Davis

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Retinal Toxicity Induced by Chemical Agents.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Prisca K LinDepartment of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida School of Medicine, Tampa, Florida.
Jocelynda SalvadorDepartment of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida School of Medicine, Tampa, Florida.
Jun XieCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Kalia N AgueraDepartment of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida School of Medicine, Tampa, Florida.
Gretchen M KollerDepartment of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida School of Medicine, Tampa, Florida.
Scott S KempDepartment of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida School of Medicine, Tampa, Florida.
Courtney T GriffinCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
George E DavisDepartment of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida School of Medicine, Tampa, Florida. Electronic address: gedavis@usf.edu.
University of South Florida · USOklahoma Medical Research Foundation · US

Funding

Molecular regulation of Rho and Ras family GTPase activity controls vascular lumen formation.R01HL126518 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI CLEAVER, ONDINE B, DAVIS, GEORGE E · 2015 to 2023
$3.1M
Priming of vascular tube morphogenesis: Novel role for VEGF and downstreamRhoA activationR01HL136139 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI CLEAVER, ONDINE B, DAVIS, GEORGE E · 2017 to 2020
$1.6M
Molecular basis for defective pericyte-endothelial cell interactions regulating vascular malformationsR01HL149748 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI DAVIS, GEORGE E · 2020 to 2023
$1.5M
NHLBI NIH HHS R01 HL126518NHLBI NIH HHS R01 HL136139NHLBI NIH HHS R01 HL149748
6 · The paper itself

Abstract

Whether alterations in the microtubule cytoskeleton affect the ability of endothelial cells (ECs) to sprout and form branching networks of tubes was investigated in this study. Bioassays of human EC tubulogenesis, where both sprouting behavior and lumen formation can be rigorously evaluated, were used to demonstrate that addition of the microtubule-stabilizing drugs, paclitaxel, docetaxel, ixabepilone, and epothilone B, completely interferes with EC tip cells and sprouting behavior, while allowing for EC lumen formation. In bioassays mimicking vasculogenesis using single or aggregated ECs, these drugs induce ring-like lumens from single cells or cyst-like spherical lumens from multicellular aggregates with no evidence of EC sprouting behavior. Remarkably, treatment of these cultures with a low dose of the microtubule-destabilizing drug, vinblastine, led to an identical result, with complete blockade of EC sprouting, but allowing for EC lumen formation. Administration of paclitaxel in vivo markedly interfered with angiogenic sprouting behavior in developing mouse retina, providing corroboration. These findings reveal novel biological activities for pharmacologic agents that are widely utilized in multidrug chemotherapeutic regimens for the treatment of human malignant cancers. Overall, this work demonstrates that manipulation of microtubule stability selectively interferes with the ability of ECs to sprout, a necessary step to initiate and form branched capillary tube networks.

Indexed as

Angiogenesis InhibitorsAnimalsBlood VesselsCells, CulturedDocetaxelEndothelial CellsEndothelium, VascularEpothilonesHumansHuman Umbilical Vein Endothelial CellsMiceMice, Inbred C57BLMorphogenesisNeovascularization, PathologicNeovascularization, PhysiologicPaclitaxelAngiogenesis InhibitorsDocetaxelepothilone BEpothilonesixabepilonePaclitaxel

Identifiers

PMID34563512
PMCPMC8647436
OpenAlexW3203319061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.